Form 4: ClearPoint Neuro Director Acquires Shares in Lieu of Fees
SEC Form 4 Filing
Director Pascal E. R. Girin acquires 525 shares of ClearPoint Neuro, Inc. common stock as payment for director fees.
Summary
- On April 1, 2025, Pascal E. R. Girin, a director of ClearPoint Neuro, Inc., acquired 525 shares of common stock.
- The shares were issued as payment for fees owed to Girin under the company's Non-Employee Director Compensation Plan.
- The price per share was $11.89, based on the closing price of ClearPoint Neuro's common stock on March 31, 2025.
- Following the transaction, Girin beneficially owns 75,018 shares of ClearPoint Neuro, Inc.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The transaction itself is routine and reflects standard compensation practices. The director increasing their stake in the company can be seen as a positive sign.
Positives
- The acquisition of shares by a director demonstrates alignment with shareholder interests.
Industry Context
This type of transaction, where directors receive shares in lieu of cash compensation, is relatively common in publicly traded companies, especially smaller ones, as it helps conserve cash and align director incentives with shareholder value.
Comparison to Industry Standards
- Many small-cap and micro-cap companies use stock-based compensation for directors to preserve cash.
- The specific amount and terms of such compensation vary widely based on company size, industry, and individual director agreements.
- Comparing ClearPoint Neuro's director compensation plan to those of similar-sized medical device companies would provide a more detailed benchmark.
Related Party Transactions
- The issuance of shares to Pascal E. R. Girin, a director, is a related party transaction.
Stakeholder Impact
- The transaction has a minor dilutive effect on existing shareholders due to the issuance of new shares.
- It aligns the director's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 1/9/2025 | Date of Power of Attorney execution. |
| 03/31/2025 | Date used to determine the closing price of CLPT common stock for share issuance. |
| 04/01/2025 | Date of the transaction where shares were acquired. |
| 04/02/2025 | Date of Form 4 filing. |
Keywords
ClearPoint Neuro, Director, Share Acquisition, Form 4, Girin, Director Fees, Compensation Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.